Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Leah Akinseye

Pediatric Endocrinology Memphis, TN Medical Doctor

NPI 1952781064 CMS profile 9834368

6215 Humphreys Blvd Ste 301, Memphis, TN 38120

Open in the dashboard

General payments

$13,778

177 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leah Akinseye of Memphis, TN is reported in the CMS Open Payments database as having received $13,778 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,135 77
2024 General $1,136 38
2023 General $1,060 36
2022 General $447 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leah Akinseye
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Leah Akinseye were reported at $11,135. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Leah Akinseye Pediatric Endocrinology median Middle half National median
2019 $0 $196 $68–$845 $163
2020 $0 $124 $37–$722 $114
2021 $0 $134 $35–$691 $132
2022 $447 $177 $47–$726 $149
2023 $1,060 $236 $75–$887 $160
2024 $1,136 $259 $91–$979 $164
2025 $11,135 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $5,129 12 payments
  2. BioMarin Pharmaceutical Inc. $4,483 10 payments
  3. Novo Nordisk Inc $654 26 payments
  4. AbbVie, Inc. $429 19 payments
  5. Insulet Corporation $372 11 payments
  6. Sequel Med Tech, LLC $352 13 payments
  7. Ascendis Pharma, Inc. $240 9 payments
  8. Xeris Pharmaceuticals, Inc. $227 12 payments
  9. Alexion Pharmaceuticals, Inc. $205 6 payments
  10. Lilly USA, LLC $182 4 payments
  11. Other $1,503 55 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,596 167 payments
  2. Consulting Fee $3,750 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,315 1 payment
  4. Travel and Lodging $2,117 8 payments
Products named General payments · program years 2022–2025
  1. VOXZOGO 1.2mg $4,460 9 payments
  2. LUPRON DEPOT $410 17 payments
  3. Omnipod $372 11 payments
  4. TWIIST $335 12 payments
  5. Ozempic $331 17 payments
  6. RYBELSUS $308 16 payments
  7. SKYTROFA $212 8 payments
  8. iLet Bionic Pancreas Automated insulin delivery system $148 1 payment
  9. iLet Bionic Pancreas Automated insulin delivery system $148 1 payment
  10. iLet Bionic Pancreas Automated insulin delivery system $148 1 payment
  11. Other $2,121 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record